• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by ENDRA Life Sciences Inc.

    5/26/26 4:59:49 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NDRA alert in real time by email
    RW 1 ea0292069-rw_endra.htm WITHDRAWAL REQUEST

    ENDRA Life Sciences Inc.

    3600 Green Court, Suite 350,

    Ann Arbor, MI 48105-1570

     

    May 26, 2026

     

    VIA EDGAR CORRESPONDENCE

     

    U.S. Securities and Exchange Commission

    Division of Corporation Finance

    100 F Street N.E.

    Washington, D.C. 20549

     

    Attention: Ms. Margaret Sawicki and Ms. Lauren Nguyen

     

    Re:ENDRA Life Sciences Inc.
    Request to Withdraw Registration Statement on Form S-1
    Filed July 9, 2025, as amended on July 16, 2025, as further amended on July 25, 2025
    File No. 333-288575

     

    Ladies and Gentlemen:

     

    Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), ENDRA Life Sciences Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of the Registrant’s Registration Statement on Form S-1 (File No. 333-288575) filed with the Commission on July 9, 2025, as amended on July 16, 2025, and as further amended on July 25, 2025, together with all exhibits thereto (collectively, the “Registration Statement”).

     

    The Registrant has decided not to pursue the offering due to business decisions and confirms that the Registration Statement has not been declared effective and no securities covered by the Registration Statement have been issued or sold. Based on the foregoing, the Registrant submits that the withdrawal of the Registration Statement is consistent with the public interest and the protection of investors.

     

    Pursuant to Rule 477 under the Securities Act, the Registrant respectfully requests that the Commission grant this application for withdrawal of the Registration Statement effective as of the date hereof or at the earliest practicable date. In accordance with Rule 457(p) under the Securities Act, the Registrant requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Registrant’s account for future use.

     

    We appreciate your time and attention to this matter. Should you have any questions, please contact Coleman Wombwell with K&L Gates LLP, the Registrant’s outside counsel, at (704) 331-7551; coleman.wombwell@klgates.com.

     

      Very truly yours,
       
      /s/ Alexander Tokman
      Alexander Tokman, Chief Executive Officer

     

    cc:Coleman Wombwell, K&L Gates LLP

     

    Get the next $NDRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NDRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NDRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

    4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    9/5/24 3:28:10 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    8/29/24 4:30:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ASP Isotopes Issues Letter to Shareholders

    DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes", "ASPI" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today released the following letter to shareholders from its Executive Chairman and Chief Executive Officer, Paul Mann. Dear Fellow Shareholder, As we prepare to announce financial results for the second quarter of 2026, I wanted to take this opportunity to update you on the developments taking place at ASP Isotopes Inc. All of our business units are making considerable progress, group revenues are increasing, and three of ou

    8/4/26 8:00:00 AM ET
    $ASPI
    $NDRA
    Major Chemicals
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

    ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value. ENDRA will continue to execute on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process. Demonstr

    5/18/26 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility

    Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independen

    5/14/26 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:18 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Digiandomenico Anthony was granted 60,324 shares, increasing direct ownership by 79% to 136,589 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    1/23/26 7:44:04 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    SEC Filings

    View All

    SEC Form 425 filed by ENDRA Life Sciences Inc.

    425 - ENDRA Life Sciences Inc. (0001681682) (Subject)

    7/17/26 8:20:15 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Inc. filed SEC Form 8-K: Other Events

    8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

    7/9/26 6:08:49 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by ENDRA Life Sciences Inc.

    SCHEDULE 13D/A - ENDRA Life Sciences Inc. (0001681682) (Subject)

    6/29/26 9:29:41 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Leadership Updates

    Live Leadership Updates

    View All

    ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

    ANN ARBOR, MI / ACCESSWIRE / June 15, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer. In this new position, Ms. Pestrikova will assume all day-to-day responsibilities previously performed by ENDRA's Chief Financial Officer David Wells, who will leave the Company effective June 18, 2021 to pursue another opportunity.Ms. Pestrikova has supported ENDRA since 2014 and has been actively involved in ENDRA's financial planning and analysis, accounting and SEC reporting functions. Previously, Ms. Pestrikova was a financial analyst at a

    6/15/21 8:35:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Financials

    Live finance-specific insights

    View All

    ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

    3/31/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC ("Nasdaq"). On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq's maintenance requirements for listing. "Now that we have regained compliance with Nasdaq's listing requirements, we can focus all our efforts on making progress on our new transformational business strategies, which we reviewed during our August 22nd conference call,

    11/22/24 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

    ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. The Company will file its quarterly report on form 10-Q with the SEC as regularly scheduled in the coming days. A press release summarizing its financial and operating results for the second quarter ending on June 30, 2024, will be issued on the day of the call. Participants are encouraged to pre-register

    8/13/24 4:05:00 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    6/14/24 4:01:26 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    6/14/24 8:00:02 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    3/10/23 12:18:14 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care